Inhibition of Phosphatidylinositol 3-kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma

Overview

Journal Cancer Res

Specialty Oncology

Date 2006 Aug 17

PMID 16912192

Citations 106

Authors

Louis Chesler

Chris Schlieve

David D Goldenberg

Anna Kenney

Grace Kim

Alex McMillan

Katherine K Matthay

David Rowitch

William A Weiss

Affiliations

Soon will be listed here.

Abstract

Amplification of MYCN occurs commonly in neuroblastoma. We report that phosphatidylinositol 3-kinase (PI3K) inhibition in murine neuroblastoma (driven by a tyrosine hydroxylase-MYCN transgene) led to decreased tumor mass and decreased levels of Mycn protein without affecting levels of MYCN mRNA. Consistent with these observations, PI3K inhibition in MYCN-amplified human neuroblastoma cell lines resulted in decreased levels of Mycn protein without affecting levels of MYCN mRNA and caused decreased proliferation and increased apoptosis. To clarify the importance of Mycn as a target of broad-spectrum PI3K inhibitors, we transduced wild-type N-myc and N-myc mutants lacking glycogen synthase kinase 3beta phosphorylation sites into human neuroblastoma cells with no endogenous expression of myc. In contrast to wild-type N-myc, the phosphorylation-defective mutant proteins were stabilized and were resistant to the antiproliferative effects of PI3K inhibition. Our results show the importance of Mycn as a therapeutic target in established tumors in vivo, offer a mechanistic rationale to test PI3K inhibitors in MYCN-amplified neuroblastoma, and represent a therapeutic approach applicable to a broad range of cancers in which transcription factors are stabilized through a PI3K-dependent mechanism.

Citing Articles

15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.

Elmenawi S, Fawzy M Curr Oncol Rep. 2025; .

PMID: 40064818 DOI: 10.1007/s11912-025-01650-w.

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.

Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.

Investigating the molecular mechanisms of Fuzheng Yiliu Shenji prescription in SH-SY5Y neuroblastoma cells.

Zhu X, Si Y, Gai C, Li Z Front Oncol. 2024; 14:1447666.

PMID: 39319058 PMC: 11420165. DOI: 10.3389/fonc.2024.1447666.

Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.

Stauffer S, Roth J, Hernandez E, Kowalczyk J, Sealover N, Hebron K Cancers (Basel). 2024; 16(13).

PMID: 39001383 PMC: 11240493. DOI: 10.3390/cancers16132320.

References

Maris J, Matthay K . Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17(7):2264-79. DOI: 10.1200/JCO.1999.17.7.2264. View

Kim S, Kang J, Qiao J, Thomas R, Evers B, Chung D . Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg. 2004; 39(4):516-21. DOI: 10.1016/j.jpedsurg.2003.12.008. View

Gregory M, Hann S . c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000; 20(7):2423-35. PMC: 85426. DOI: 10.1128/MCB.20.7.2423-2435.2000. View

Schmidt M, Lukens J, Seeger R, Brodeur G, Shimada H, Gerbing R . Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol. 2000; 18(6):1260-8. DOI: 10.1200/JCO.2000.18.6.1260. View

Weiss W, Godfrey T, Francisco C, Bishop J . Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res. 2000; 60(9):2483-7. View

Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H . MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol. 2000; 476:239-48. DOI: 10.1007/978-1-4615-4221-6_19. View

Knight Z, Chiang G, Alaimo P, Kenski D, Ho C, Coan K . Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004; 12(17):4749-59. DOI: 10.1016/j.bmc.2004.06.022. View

Zhou B, Deng J, Xia W, Xu J, Li Y, Gunduz M . Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6(10):931-40. DOI: 10.1038/ncb1173. View

Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F . GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004; 16(1):35-45. DOI: 10.1016/j.molcel.2004.09.004. View

10.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

11.

Thiele C, Reynolds C, Israel M . Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985; 313(6001):404-6. DOI: 10.1038/313404a0. View

12.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res. 1985; 175:105-13. View

13.

Seeger R, Brodeur G, Sather H, Dalton A, Siegel S, Wong K . Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111-6. DOI: 10.1056/NEJM198510313131802. View

14.

Zimmerman K, Yancopoulos G, Collum R, Smith R, Kohl N, Denis K . Differential expression of myc family genes during murine development. Nature. 1986; 319(6056):780-3. DOI: 10.1038/319780a0. View

15.

Semsei I, Ma S, Cutler R . Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain. Oncogene. 1989; 4(4):465-71. View

16.

Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M . Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res. 1990; 50(14):4411-6. View

17.

Cohn S, Salwen H, Quasney M, Ikegaki N, Cowan J, Herst C . Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene. 1990; 5(12):1821-7. View

18.

Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A, Raschella G . Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 1991; 2(10):511-8. View

19.

Martin D, Feldman E . Regulation of insulin-like growth factor-IL expression and its role in autocrine growth of human neuroblastoma cells. J Cell Physiol. 1993; 155(2):290-300. DOI: 10.1002/jcp.1041550210. View

20.

Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y . Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993; 268(34):25846-56. View